Lower prevalence of osteoporosis in patients with COPD taking anti-inflammatory compounds for the treatment of diabetes

• Verfasst von: Kahnert, Kathrin [VerfasserIn]
• Verfasst von: Jörres, Rudolf A. [VerfasserIn]
• Verfasst von: Lucke, Tanja [VerfasserIn]
• Verfasst von: Trudzinski, Franziska [VerfasserIn]
• Verfasst von: Mertsch, Pontus [VerfasserIn]
• Verfasst von: Bickert, Christiane [VerfasserIn]
• Verfasst von: Ficker, Joachim H. [VerfasserIn]
• Verfasst von: Behr, Jürgen [VerfasserIn]
• Verfasst von: Bals, Robert [VerfasserIn]
• Verfasst von: Watz, Henrik [VerfasserIn]
• Verfasst von: Welte, Tobias [VerfasserIn]
• Verfasst von: Vogelmeier, Claus F. [VerfasserIn]
• Verfasst von: Alter, Peter [VerfasserIn]
• Titel: Lower prevalence of osteoporosis in patients with COPD taking anti-inflammatory compounds for the treatment of diabetes
• Titelzusatz: results from COSYCONET
• Verf.angabe: Kathrin Kahnert, Rudolf A Jörres, Tanja Lucke, Franziska C Trudzinski, Pontus Mertsch, Christiane Bickert, Joachim H Ficker, Jürgen Behr, Robert Bals, Henrik Watz, Tobias Welte, Claus F Vogelmeier, Peter Alter, on behalf of COSYCONET study group
• E-Jahr: 2021
• Jahr: 24 November 2021
• Umfang: 11 S.
• Fussnoten: Gesehen am 26.01.2022
• Titel Quelle: Enthalten in: The International journal of chronic obstructive pulmonary disease
• Ort Quelle: Albany, Auckland : DOVE Medical Press, 2006
• Jahr Quelle: 2021
• Band/Heft Quelle: 16(2021), Seite 3189-3199
• ISSN Quelle: 1178-2005
• DOI: doi:10.2147/COPD.S335029
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1787168727

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) often have osteoporosis and diabetes as comorbid conditions. Anti-diabetic medication, including met­ formin, has protective effects on osteoporosis in experimental studies. We therefore studied whether patients with COPD receiving anti-diabetic medication had a lower osteoporosis prevalence in a large COPD cohort, COSYCONET. - Methods: Assessment of osteoporosis was based on patients’ reports of physician-based diagnoses and the presence of disease-specific medication. The predictive value of physical characteristics, lung function, comorbidities, cardiovascular medication, and the use of antiinflammatory diabetes medication, including metformin, sulfonylureas, glinides or DPP4I, was evaluated using logistic regression analysis. ClinicalTrials.gov: NCT01245933. - Results: In total, 2222 patients were eligible for analysis (863 [39%] female, mean age 65 y), 515 of whom had higher symptoms and exacerbations (Global Initiative for Chronic Obstructive Lung Disease group D). Osteoporosis was present in 15.8% of the overall cohort, and in 24.1% of GOLD D patients. Regression analyses identified the following as associated with osteoporosis (p < 0.05): female sex, higher age, lower body-mass index, asthma, higher air trapping, oral steroids, and cardiovascular medication. Although oral anti-diabetic medication was overall not associated with a lower prevalence of osteoporosis (p = 0.131), anti-inflammatory anti-diabetic medication (p = 0.009) and metformincontaining therapy (p = 0.039) were. This was driven by GOLD D patients. - Conclusion: In a large COPD cohort, anti-inflammatory diabetes therapy, including metformin, was associated with a lower prevalence of osteoporosis, especially in patients with higher symptoms and exacerbations. These findings suggest a protective effect of common antidiabetic medication on osteoporosis, possibly as a result of attenuated systemic inflammation.